Smith says there have been some preliminary results with antipsychotics, such as Zyprexa, Risperdal and Seroquel.
The question, then, is whether Zyprexa can make up for the loss of Prozac.
Lilly lists its antipsychotic drug Zyprexa among those that will lose their patents this year.
FORBES: Big Pharma Outlook Still Bearish After Mixed Earnings
One possible reason: controversy over Zyprexa's potential to cause weight gain in some patients.
What investors want to see are some new drugs to replace Zyprexa and the others.
And, at low doses, Zyprexa and AstraZeneca's Seroquel are often given as a sleep or calming aid.
Some Telorzan contained 17 times the level of impurities that would be expected in U.S. Zyprexa pills.
In 2007, Lilly added to Zyprexa's label a more specific warning about the potential for weight gain.
Lilly's own studies show that Zyprexa doubles the risk of stroke death when given to elderly dementia patients.
Meanwhile, some worry that Lilly's current sales leader, Zyprexa, can't hold off new competition in the schizophrenia market.
This may be what happened to the schizophrenia drug Lilly was developing as an heir to its top-seller, Zyprexa.
Lilly loses patent protection on its top-seller, the schizophrenia drug Zyprexa, in 2011.
Abilify isn't as powerful as Zyprexa, but it seems to have fewer side effects, including causing less weight gain.
FORBES: Bristol's Earnings Restatement: Prelude To A Merger?
But his muscle spasms returned, though studies said they were uncommon with Zyprexa.
Also, he warned that the higher dose of Zyprexa might bias the results.
If Zyprexa does come out ahead, competitors will jump all over this fact.
And Zyprexa won't be the only product that Lilly will be counting on.
Zyprexa, a treatment for schizophrenia, has taken its place as Lilly's top drug.
Prescriptions for Zyprexa in the U.S. have dropped more than 20% even as the overall market for antipsychotics has grown.
AstraZeneca is seeking approval to market Seroquel for treating children, and Eli Lilly is asking for the same for Zyprexa.
When the NABP investigators ordered Zyprexa, Lilly's top-selling antipsychotic, they got something called Telorzan, packaged in a cheap-looking blue box.
Next month, the agency will consider another hot-button topic: the overuse of antipsychotic drugs like Risperdal and Zyprexa in children.
For instance, Eli Lilly, which is up about 15% this year, is facing its own battle over its top seller, Zyprexa.
For Lilly, the day of reckoning was Oct. 25, 2011, when competitors announced a generic version of Zyprexa, an antipsychotic medication.
Also, she said, Lilly representatives downplayed the weight gain that Dr. McKinney saw among some patients taking the company's blockbuster antipsychotic Zyprexa.
Perphenazine is cheap, and Zyprexa is more expensive than the other medicines.
Eli Lilly's Zyprexa, Glaxo's Zantac and Novartis' Zelnorm are all GPCR-related drugs.
Zyprexa, an anti-psychotic drug, replaced it as Lilly's biggest source of revenue.
Norman Sussman, head of psychiatry at New York University, says that Zyprexa works fast but has been connected with weight gain in his experience.
Several months ago Lilly sent a letter to Zyprexa prescribers offering to help them line up defense attorneys and scientific experts if they are sued.
应用推荐